{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"61.1","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"The main primary endpoint of this study is two-year progression free survival. Patients are considered a failure with respect to PFS if they die or experience disease progression or relapse. The time to this event is the time from transplantation to relapse/progression, initiation of non-protocol anti-myeloma therapy, or death from any cause. Subjects alive without confirmed disease progression will be censored at the time of last disease evaluation. Deaths without progression are treated as failures no matter when they occur.","dispersionType":"Full Range","groups":[{"description":"Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.\n\n* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2\n* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.","id":"OG000","title":"Fludarabine, Melphalan, Bortezomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Subjects will be followed for progression-free survival for at least 36 months","title":"Progression Free Survival","type":"PRIMARY","unitOfMeasure":"Months"}